JAK-inhibitor safety in adolescents with AD: Long-term analyses reported.

The article focuses on the long-term safety of JAK inhibitors, specifically abrocitinib and upadacitinib, in adolescents with moderate to severe atopic dermatitis (AD). The topics covered include the acceptable safety profile of abrocitinib in adolescents with over 96 weeks of exposure; the absence of unique safety concerns in adolescents compared to adults; and also mentions the similar safety profile of upadacitinib in adolescents and adults with up to 4 years of treatment..